{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:18:47Z","timestamp":1765462727697,"version":"3.48.0"},"reference-count":92,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Hereditary angioedema (HAE) is a rare hereditary disease characterized by edema, which can be life\u2010threatening in case of swelling in the larynx. The most common form of HAE is caused by a mutation of the\n                    <jats:italic>SERPING1<\/jats:italic>\n                    gene and is characterized by a deficiency (type\u00a0I) or loss of function (type\u00a0II) of the C1 inhibitor (C1\u2010INH), leading to excessive production of bradykinin. In contrast, the HAE\u2010nC1\u2010INH entity is associated with a normal C1\u2010INH protein and is caused by mutations in other genes. Because HAE is a rare and often underdiagnosed disease, it may take years from symptom onset to diagnosis. The angioedema attacks cause suffering and affect both the ability to work and quality of life (QoL). The treatment of HAE includes attack treatment (on\u2010demand), short\u2010term prophylaxis (e.g., before medical procedures), and long\u2010term prophylaxis. Four first\u2010line treatment options for long\u2010term prophylaxis are available, effectively preventing attacks and supporting the guideline goal of complete disease control. Further treatment options, including CRISPR\/Cas9\u2010based gene therapy, are under development and promise to provide individually tailored treatment for patients. This review aims to provide an overview of the clinical presentation, diagnosis, and treatment of HAE.\n                  <\/jats:p>","DOI":"10.1111\/ddg.15889","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:59:01Z","timestamp":1756983541000},"page":"1512-1525","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Status quo and future developments in the diagnosis and treatment of hereditary angioedema"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-1804","authenticated-orcid":false,"given":"Andreas","family":"Recke","sequence":"first","affiliation":[{"name":"Department of Dermatology Allergology and Venereology University Hospital Schleswig\u2010Holstein \u2013 L\u00fcbeck Campus  L\u00fcbeck Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"1","key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"S08","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry WR","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0815-5"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.12.023"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03265-z"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.055"},{"issue":"99","key":"e_1_2_11_7_1","first-page":"1","article-title":"Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe","volume":"9","author":"Ayg\u00f6ren\u2010P\u00fcrs\u00fcn E","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3623"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.02.018"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200081"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.05.020"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.03.024"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23917"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1808012"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16667-w"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2014.0425"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152509789105444"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1146834"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.051"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10092023"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100223"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.05.017"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.009"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.049"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12186"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2011.02.034"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/lio2.555"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-018-0088-5"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15012-022-6896-9"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep09066"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.01.015"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1048480"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12209"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12900"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01717-4"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.12.010"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00550-5"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9157895"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00537-2"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12758"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12712"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2013.34.3685"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2014"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091217419837068"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2021.42.200127"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.07.017"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2013.12.004"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906393"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200058"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200066"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1090732"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14454"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13349"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514973:1\u20108"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613627"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15011"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14785"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.057"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.12.019"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12035"},{"issue":"11","key":"e_1_2_11_62_1","article-title":"Interventions for the long\u2010term prevention of hereditary angioedema attacks","volume":"11","author":"Beard N","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15154_g"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915035"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109329"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402478"},{"key":"e_1_2_11_67_1","unstructured":"ClinicalTrails.gov.OASIS\u2010HAE: a study to evaluate the safety and efficacy of donidalorsen (ISIS 721744 or IONIS\u2010PKK\u2010LRx) in participants with hereditary angioedema (HAE).2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05139810(Last accessed on August 23 2024)."},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.091"},{"key":"e_1_2_11_69_1","unstructured":"ClinicalTrails.gov.Dose\u2010ranging study of oral PHA\u2010022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (RAPIDe\u20101).2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04618211. (Last accessed on January 17 2024)."},{"key":"e_1_2_11_70_1","unstructured":"ClinicalTrails.gov.Dose\u2010ranging study of oral PHA\u2010022121 for prophylaxis against angioedema attacks in patients with hereditary angioedema type I or type II (HAE CHAPTER\u20101).2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05047185. (Last accessed on January 17 2024)."},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.122"},{"key":"e_1_2_11_72_1","unstructured":"MagerlM AndersonJ Ayg\u00f6ren\u2010P\u00fcrs\u00fcnE BaezaML.Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate\u2010release capsule for treatment of hereditary angioedema attacks: results of RAPIDe\u20101 phase 2 trial. HAEi Regional Conference Americas Panama City Panama.2024. Available from:https:\/\/ir.pharvaris.com\/static\u2010files\/98210361\u20100a77\u201041d9\u2010b04a\u2010f87d6a142775. (Last accessed on August 27 2024)."},{"volume-title":"Efficacy and safety of oral deucrictibant, a bradykinin B2 receptor antagonist, in prophylaxis of hereditary angioedema attacks: results of CHAPTER\u20101 phase 2 trial. EAACI 2024","year":"2024","author":"Ayg\u00f6ren\u2010P\u00fcrs\u00fcn E","key":"e_1_2_11_73_1"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.11.011"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001740"},{"key":"e_1_2_11_77_1","unstructured":"ClinicalTrails.gov.A study of STAR\u20100215 in healthy adult participants.2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05477160. (Last accessed on January 17 2024)."},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.08.107"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314192"},{"key":"e_1_2_11_80_1","unstructured":"ClinicalTrails.gov.A phase III crossover trial evaluating the efficacy and safety of KVD900 for on\u2010demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).2024. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05259917(Last accessed on August 23 2024)."},{"key":"e_1_2_11_81_1","unstructured":"KalVista.Pharmaceuticals announces termination of KVD824 phase 2 KOMPLETE trial for prophylactic treatment of hereditary angioedema.2022. Available from:https:\/\/ir.kalvista.com\/news\u2010releases\/news\u2010release\u2010details\/kalvista\u2010pharmaceuticals\u2010announces\u2010termination\u2010kvd824\u2010phase\u20102\/(Last accessed on August 27 2024)."},{"key":"e_1_2_11_82_1","article-title":"Updated safety and efficacy of NTLA\u20102002, a CRISPR\/Cas9\u2010based gene editing therapy targeting KLKB1, in a phase 1 study of patients with hereditary angioedema (poster presentation)","author":"Cohn DM","year":"2023","journal-title":"Acad Allergy Clin Immunol., Annual Meeting"},{"key":"e_1_2_11_83_1","unstructured":"ClinicalTrails.gov.NTLA\u20102002 in adults with hereditary angioedema (HAE) (NTLA\u20102002).2024. Available from:https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05120830. (Last accessed on January 17 2024)."},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309149"},{"key":"e_1_2_11_85_1","unstructured":"HAEi.BioMarin announces discontinuation of BMN 331 an investigational medicine for HAE.2024. Available from:https:\/\/haei.org\/biomarin\u2010announces\u2010discontinuation\u2010of\u2010bmn\u2010331\u2010an\u2010investigational\u2010medicine\u2010for\u2010hae\/. (Last accessed on August 27 2024)."},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2023.1143897"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01506-5"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.278"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2020.03099"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.008"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2020.41.200065"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.012"},{"key":"e_1_2_11_93_1","unstructured":"Fachinfo\u2010Service.Fachinformationsverzeichnis Deutschland 2024. Available from:www.fachinfo.de. (Last accessed on January 17 2024)."}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T14:14:41Z","timestamp":1765462481000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":92,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/ddg.15889"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15889","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"2024-11-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}